#Signals #ObesityMedicine #GLP1 #MetabolicHealth To view or add a comment, sign in REDEFINE 5: A Step Forward in Obesity Management The Phase 3a REDEFINE 5 trial demonstrated that cagrilintide + semaglutide achieved significantly greater weight loss than semaglutide alone at 68 weeks (18.4% vs 11.9%), highlighting the potential of dual amylinGLP-1 therapy as a next-generation approach to obesity treatment
The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease
3.2 Peripheral GLP-1 signalling in taste pathways: cellular plausibility and translational limits Preclinical studies indicate that GLP-1 is produced in distinct subpopulations of mammalian taste bud cells (TBCs) (13), including TAS1R3-positive and gustducin-positive type II cells, as well as a subset of serotonin-containing type III cells (38)
Thats why its important to approach this combination cautiously especially if you have underlying health conditions or are taking other medications
A short-term increase can be reasonable during high-stress recovery periods, but benefits plateau at higher doses